Penumbra, Inc. reported a strong second quarter with a 25.5% increase in revenue, reaching $261.5 million. The company's income from operations turned positive, reaching $17.9 million, compared to a loss in the same quarter last year. They are also increasing their revenue guidance for the year.
Total revenue increased to $261.5 million, a 25.5% increase compared to Q2 2022.
Vascular product revenue grew to $152.7 million, a 23.6% increase.
Neuro product revenue grew to $108.8 million, a 28.3% increase.
Income from operations was $17.9 million, compared to a loss of $0.1 million in Q2 2022.
The Company is increasing its guidance for 2023 total revenue to be in the range of $1.05 billion to $1.07 billion, which represents 24% to 26% growth over 2022 revenue of $847.1 million. We continue to expect growth in our global vascular business to be slightly above this range and growth in our global neuro business to be below this range for the full year 2023.
Visualization of income flow from segment revenue to net income